Prelude Therapeutics Statistics
Share Statistics
Prelude Therapeutics has 56.46M
shares outstanding. The number of shares has increased by 0.41%
in one year.
| Shares Outstanding | 56.46M |
| Shares Change (YoY) | 0.41% |
| Shares Change (QoQ) | 0.22% |
| Owned by Institutions (%) | 42.4% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 6,773 |
| FTD / Avg. Volume | 3.67% |
Short Selling Information
The latest short interest is 978.61K, so 1.73% of the outstanding
shares have been sold short.
| Short Interest | 978.61K |
| Short % of Shares Out | 1.73% |
| Short % of Float | 13.26% |
| Short Ratio (days to cover) | 8.26 |
Valuation Ratios
The PE ratio is -0.76 and the forward
PE ratio is -0.85.
Prelude Therapeutics's PEG ratio is
0.04.
| PE Ratio | -0.76 |
| Forward PE | -0.85 |
| PS Ratio | 13.75 |
| Forward PS | 0.6 |
| PB Ratio | 0.73 |
| P/FCF Ratio | -0.93 |
| PEG Ratio | 0.04 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Prelude Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.3,
with a Debt / Equity ratio of 0.14.
| Current Ratio | 5.3 |
| Quick Ratio | 5.3 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | -0.13 |
| Debt / FCF | -0.17 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $53,435.11 |
| Profits Per Employee | $-970,786.26 |
| Employee Count | 131 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -73.58% in the
last 52 weeks. The beta is 1.29, so Prelude Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.29 |
| 52-Week Price Change | -73.58% |
| 50-Day Moving Average | 0.77 |
| 200-Day Moving Average | 1.88 |
| Relative Strength Index (RSI) | 63.05 |
| Average Volume (20 Days) | 184,377 |
Income Statement
In the last 12 months, Prelude Therapeutics had revenue of 7M
and earned -127.17M
in profits. Earnings per share was -1.68.
| Revenue | 7M |
| Gross Profit | 5.23M |
| Operating Income | -139.71M |
| Net Income | -127.17M |
| EBITDA | -139.71M |
| EBIT | -139.71M |
| Earnings Per Share (EPS) | -1.68 |
Full Income StatementBalance Sheet
The company has 12.47M in cash and 18.02M in
debt, giving a net cash position of -5.55M.
| Cash & Cash Equivalents | 12.47M |
| Total Debt | 18.02M |
| Net Cash | -5.55M |
| Retained Earnings | -583.56M |
| Total Assets | 175.51M |
| Working Capital | 110.25M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -102.89M
and capital expenditures -764K, giving a free cash flow of -103.65M.
| Operating Cash Flow | -102.89M |
| Capital Expenditures | -764K |
| Free Cash Flow | -103.65M |
| FCF Per Share | -1.37 |
Full Cash Flow StatementMargins
Gross margin is 74.69%, with operating and profit margins of -1995.91% and -1816.76%.
| Gross Margin | 74.69% |
| Operating Margin | -1995.91% |
| Pretax Margin | -1816.76% |
| Profit Margin | -1816.76% |
| EBITDA Margin | -1995.91% |
| EBIT Margin | -1995.91% |
| FCF Margin | -1480.74% |
